Jianggan District
Hangzhou ZHJ 310016
P: +86571.85802712
Hangzhou ZHJ 310016
P: +86571.85802712
Company Web Links
IDA Pharmaceuticals, Inc., incorporated in December 18, 2002, and located in Hangzhou, the People’s Republic of China, operates through its subsidiaries, which include Earjoy Group Limited (Earjoy), Hangzhou Aida Pharmaceutical Co., Ltd (Hangzhou Aida), Hangzhou Boda Medical Research and Development Co., Ltd. (Boda), Hainan Aike Pharmaceutical Co., Ltd. (Aike), Changzhou Fangyuan Pharmaceutical Co., Ltd. (Fangyuan) and Shanghai Qiaer Bio-technology Co., Ltd (Qiaer). Earjoy is an investment holding company. Hangzhou Aida is a pharmaceutical company engaged in the development, manufacture, marketing, licensing, and distribution of pharmaceutical products primarily in mainland China. Hangzhou Aida has a total of nine production lines for the manufacture of antibiotics, cardiovascular and anti-tumor drugs in various forms, including injectable powder, injectable liquid, capsules, tablets and ointments. Hangzhou Aida’s primary product is the injectable powder form of Etimicin Sulfate.
Boda is a wholly owned subsidiary of Hangzhou Aida and engages itself in the research and development of new drugs. Aike specializes in the production of transfusion type of Etimicin AiYi. Fangyuan is a 66%-owned subsidiary of Hangzhou Aida. Fangyuan is a supplier of raw material for Etimicin and is also a producer of the liquid type of Etimicin ChuangCheng. The key product of Qiaer is Apoptotic Factor (rh-Apo2l), a potential biopharmaceutical therapy with genetic engineering techniques used for cancers.
On March 26, 2008, Hangzhou Aida signed a purchase agreement with Jin’ou Medicine Co., Ltd to acquire a 43% equity interest in Jiangsu Institute of Microbiology Co., Ltd. On March 26, 2008, Fangyuan signed a purchase agreement with Jiangyin Hi-tech Group to acquire 55% interest in Jiangsu Institute of Microbiology Co., Ltd.
Etimicin Sulfate is an amino glycoside family of antibiotics. It is suitable for the treatment of various inflammations, including respiratory infection, such as acute bronchitis, acute onset of chronic bronchitis and pulmonary infections; kidney and urinogenital infection, such as acute pyelonephritis or acute onset of chronic cystitis; soft skin tissue infection, and trauma and operations (before and after) preventive uses.
The products being developed by AIDA Pharmaceuticals include rh-Apo2l, Vasostatin –Apo2L, Prodigiosin, Anti-CD86 Monoclonal Antibody and Anti-CTLA-4 Monoclonal Antibody. Rh-Apo2l is being evaluated in a Phase II trial which started in February 2007. Vasostatin –Apo2L is a recombinant fusion protein that is being tested as a potential cancer drug. It integrates the function of extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of rh-Apo2l which induces the apoptosis of cancer cells. Prodigiosin, a naturally occurring red pigment, is in pre-clinical trials for the treatment of pancreatic cancer.
Certain immunity diseases activate T-cells (a type of white blood cell), causing them to unnecessarily attack healthy tissue. Anti-CD86 Monoclonal Antibody inhibits T-cells from harming healthy tissue. In the case of certain cancers, tumors over-express self-proteins, essentially hiding the tumor from the immune system. The Company is in the development stages of an Anti-CTLA-4 Monoclonal Antibody, which may relieve the inhibition of T-cells allowing them to identify the over-expressed proteins and in turn naturally attacking cancer cells without harming healthy tissues.
AIDA Pharmaceuticals's main production facilities are located in Hangzhou in the Zhejiang Province, in Changzhou in the Jiangsu Province and in Haikou in the Hainan Province. The raw materials and supplies for manufacturing at the plants are sourced from suppliers in China. The supplier for Etimicin Sulfate base aside from Fangyuan is Shanhe Pharmaceuticals Co., Ltd. in Wuxi, Jiangsu Province.
In the Goldbug 100 portolio - the Fund Manager feels that a HKSE listing would be better for this company than the current Pink Sheet one, but of course the listing costs may prohibit this. Price paid $1.15 at the peak of the bull market in 2008. The fund does not like the reporting of Pink Sheet shares. AIM on the London Stock Exchange shows potential investors far more details.
.
.
Important information for the investor - Price earning ratio / assets per share and of course future dividend policy etc. The fund in view of the lack of reporting of Pink Sheet shares really is reluctant to "average out" on it´s holdings in PS companies which are more suitable to "day traders" and are the fodder of "Pump and dump" internet web sites who paint a rosy picture of their client´s prospects
